Subject category:
Strategy and General Management
Published in:
2000
Length: 37 pages
Data source: Published sources
Share a link:
https://casecent.re/p/22233
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
This note offers a layman''s account of the basics of what biotechnology is and the nature of competition facing therapeutic (drug) biotechnology firms. An overview of the various stages of the R&D process that firms undertake to obtain regulatory approval for the marketing of a drug is provided. A table summarises the time, cost, and probabilities of success at each stage of the process. The relationship between small entrepreneurial biotechnology firms and pharmaceutical firms is explored. Insights are offered into the financial health, strategy and R&D portfolios of eight biotechnology firms listed on the London Stock Exchange. These firms are British Biotech, Cantab, Celltech, Chiroscience, Oxford Molecular, Proteus International, Peptide Therapeutics and Scotia Holdings. Tables are provided detailing their performance on the LSE, R&D and alliance portfolios and cash positions. This note may be used as a companion to ''The Rejuvenation of Celltech in the 1990s'' (300- 072-1).
Subject category:
Strategy and General Management
Published in:
2000
Length: 60 pages
Subject category:
Strategy and General Management
Published in:
2000
Length: 31 pages
Data source: Field research
About
Abstract
This note offers a layman''s account of the basics of what biotechnology is and the nature of competition facing therapeutic (drug) biotechnology firms. An overview of the various stages of the R&D process that firms undertake to obtain regulatory approval for the marketing of a drug is provided. A table summarises the time, cost, and probabilities of success at each stage of the process. The relationship between small entrepreneurial biotechnology firms and pharmaceutical firms is explored. Insights are offered into the financial health, strategy and R&D portfolios of eight biotechnology firms listed on the London Stock Exchange. These firms are British Biotech, Cantab, Celltech, Chiroscience, Oxford Molecular, Proteus International, Peptide Therapeutics and Scotia Holdings. Tables are provided detailing their performance on the LSE, R&D and alliance portfolios and cash positions. This note may be used as a companion to ''The Rejuvenation of Celltech in the 1990s'' (300- 072-1).
Settings
Related
Subject category:
Strategy and General Management
Published in:
2000
Length: 60 pages
Subject category:
Strategy and General Management
Published in:
2000
Length: 31 pages
Data source: Field research